The kallikrein world: an update on the human tissue kallikreins

References

Bakin, R.E., Gioeli, D., Sikes, R.A., Bissonette, E.A., and Weber, M.J. (2003). Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res.63, 1981–1989.Search in Google Scholar

Bayes, A., Tsetsenis, T., Ventura, S., Vendrell, J., Aviles, F.X., and Sotiropoulou, G. (2004). Human kallikrein 6 activity is regulated via an autoproteolytic mechanism of activation/inactivation. Biol. Chem.385, 517–524.10.1515/BC.2004.061Search in Google Scholar PubMed

Black, M.H., Magklara, A., Obiezu, C.V., Melegos, D.N., and Diamandis, E.P. (1999) Development of ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen. Clin. Chem.45, 790–799.10.1093/clinchem/45.6.790Search in Google Scholar

Blok, L.J., de Ruiter, P.E., and Brinkmann, A.O. (1998). Forskolin-induced dephosphorylation of the androgen receptor impairs ligand binding. Biochemistry37, 3850–3857.10.1021/bi9724422Search in Google Scholar PubMed

Borgono, C.A. and Diamandis, E.P. (2004). The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer4, 876–890.10.1038/nrc1474Search in Google Scholar PubMed

Borgono, C.A., Grass, L., Soosaipillai, A., Yousef, G.M., Petraki, C.D., Howarth, D.H., Fracchioli, S., Katsaros, D., and Diamandis, E.P. (2003). Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res.63, 9032–9041.Search in Google Scholar

Borgono, C.A., Michael, I.P., and Diamandis, E.P. (2004). Human tissue kallikreins: physiologic roles and applications in cancer. Mol. Cancer Res.2, 257–280.10.1158/1541-7786.257.2.5Search in Google Scholar

Caubet, C., Jonca, N., Brattsand, M., Guerrin, M., Bernard, D., Schmidt, R., Egelrud, T., Simon, M., and Serre, G. (2004). Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J. Invest. Dermatol.122, 1235–1244.10.1111/j.0022-202X.2004.22512.xSearch in Google Scholar PubMed

Chavanas, C., Bodemer, C., Rochat, A., Hamel-Teillac, D., Ali, M., Irvine, A.D., Bonafe, J.L., Wilkinson, J., Taieb, A., Barrandon, Y., et al. (2000). Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat. Genet.25, 141–142.10.1038/75977Search in Google Scholar PubMed

Cleutjens, K.B., van Eekelen, C.C., van der Korput, H.A., Brinkmann, A.O., and Trapman, J. (1996). Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J. Biol. Chem.271, 6379–6388.10.1074/jbc.271.11.6379Search in Google Scholar PubMed

Cloutier, S.M., Chagas, J.R., Mach, J.P., Gygi, C.M., Leisinger, H.J., and Deperthes, D. (2002). Substrate specificity of human kallikrein 2 (hK2) as determined by phage display technology. Eur. J. Biochem.269, 2747–2754.10.1046/j.1432-1033.2002.02960.xSearch in Google Scholar PubMed

Cloutier, S.M., Kundig, C., Felber, L.M., Fattah, O.M., Chagas, J.R., Gygi, C.M., Jichlinski, P., Leisinger, H.J., and Deperthes, D. (2004). Development of recombinant inhibitors specific to human kallikrein 2 using phage-display selected substrates. Eur. J. Biochem.271, 607–613.10.1111/j.1432-1033.2003.03963.xSearch in Google Scholar PubMed

Cohen, P., Graves, H.C., Peehl, D.M., Kamarei, M., Giudice, L.C., and Rosenfeld, R.G. (1992). Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J. Clin. Endocrinol. Metab.75, 1046–1053.Search in Google Scholar

de Koning, H.J., Auvinen, A., Berenguer Sanchez, A., Calais da Silva, F., Ciatto, S., Denis, L., Gohagan, J.K., Hakama, M., Hugosson, J., Kranse, R., et al. (2002). Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int. J. Cancer97, 237–244.10.1002/ijc.1588Search in Google Scholar

DeGraffenried, L.A., Fulcher, L., Friedrichs, W.E., Grunwald, V., Ray, R.B., and Hidalgo, M. (2004). Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann. Oncol.15, 1510–1516.10.1093/annonc/mdh388Search in Google Scholar

Descargues, P., Deraison, C., Bonnart, C., Kreft, M., Kishibe, M., Ishida-Yamamoto, A., Elias, P., Barrandon, Y., Zambruno, G., Sonnenberg, A., and Hovnanian, A. (2005). Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity. Nat. Genet.37, 56–65.10.1038/ng1493Search in Google Scholar

Diamandis, E.P., Yousef, G.M., Soosaipillai, A.R., and Bunting, P. (2000a). Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. Clin. Biochem.33, 579–583.10.1016/S0009-9120(00)00182-XSearch in Google Scholar

Diamandis, E.P., Yousef, G.M., Clements, J., Ashworth, L.K., Yoshida, S., Egelrud, T., Nelson, P.S., Shiosaka, S., Little, S., Lilja, H., et al. (2000b). New nomenclature for the human tissue kallikrein gene family. Clin. Chem.46, 1855–1858.10.1093/clinchem/46.11.1855Search in Google Scholar

Diamandis, E.P., Okui, A., Mitsui, S., Luo, L.Y., Soosaipillai, A., Grass, L., Nakamura, T., Howarth, D.J., and Yamaguchi, N. (2002). Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res.62, 295–300.Search in Google Scholar

Diamandis, E.P., Scorilas, A., Fracchioli, S., Van Gramberen, M., De Bruijn, H., Henrik, A., Soosaipillai, A., Grass, L., Yousef, G.M., Stenman, U.H., et al. (2003). Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis of ovarian carcinoma. J. Clin. Oncol.21, 1035–1043.10.1200/JCO.2003.02.022Search in Google Scholar

Felber, L.M., Borgono, C.A., Cloutier, S.M., Kundig, C., Kishi, T., Ribeiro Chagas, J., Jichlinski, P., Gygi, C.M., Leisinger, H.J., Diamandis, E.P., and Deperthes, D. (2005). Enzymatic profiling of human kallikrein 14 using phage-display substrate technology. Biol. Chem.386, 291–298.10.1515/BC.2005.035Search in Google Scholar

Ferguson, R.A., Yu, H., Kalyvas, M., Zammit, S., and Diamandis, E.P. (1996). Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clin. Chem.42, 675–684.10.1093/clinchem/42.5.675Search in Google Scholar

Frenette, G., Tremblay, R.R., Lazure, C., and Dube, J.Y. (1997). Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator. Int. J. Cancer71, 897–899.10.1002/(SICI)1097-0215(19970529)71:5<897::AID-IJC31>3.0.CO;2-2Search in Google Scholar

Ghosh, M.C., Grass, L., Soosaipillai, A., Sotiropoulou, G., and Diamandis, E.P. (2004). Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells. Tumour Biol.25, 193–199.10.1159/000081102Search in Google Scholar

Hoffman, B.R., Katsaros, D., Scorilas, A., Diamandis, P., Fracchioli, S., Rigault de la Longrais, I.A., Colgan, T., Puopolo, M., Giardina, G., Massobrio, M., and Diamandis, E.P. (2002). Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker. Br. J. Cancer87, 763–771.10.1038/sj.bjc.6600533Search in Google Scholar PubMed PubMed Central

Hollenberg, M.D. and Compton, S.J. (2002). International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol. Rev.54, 203–217.Search in Google Scholar

Jayakumar, A., Kang, Y., Mitsudo, K., Henderson, Y., Frederick, M.J., Wang, M., El-Naggar, A.K., Marx, U.C., Briggs, K., and Clayman, G.L. (2004). Expression of LEKTI domains 6–9′ in the baculovirus expression system: recombinant LEKTI domains 6–9′ inhibit trypsin and subtilisin A. Protein Expr. Purif.35, 93–101.10.1016/j.pep.2003.12.004Search in Google Scholar PubMed

Jemal, A., Tiwari, R.C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E.J., and Thun, M.J. (2004). Cancer statistics, 2004. CA Cancer J. Clin.54, 8–29.10.3322/canjclin.54.1.8Search in Google Scholar PubMed

Jonsson, M., Linse, S., Frohm, B., Lundwall, A., and Malm, J. (2005). Semenogelins I and I bind zinc and regulate the activity of prostate-specific antigen. Biochem. J.387, 447–453.10.1042/BJ20041424Search in Google Scholar PubMed PubMed Central

Kapadia, C., Chang, A., Sotiropoulou, G., Yousef, G.M., Grass, L., Soosaipillai, A., Zing, X., Howarth, D.H., and Diamandis, E.P. (2003). Human kallikrein 13: production and purification of recombinant protein and monoclonal and polyclonal antibodies, and development of a sensitive and specific immunofluorometric assay. Clin. Chem.49, 77–86.10.1373/49.1.77Search in Google Scholar PubMed

Kapadia, C., Ghosh, M.C., Grass, L., and Diamandis, E.P. (2004a). Human kallikrein 13 involvement in extracellular matrix degradation. Biochem. Biophys. Res. Commun.323, 1084–1090.10.1016/j.bbrc.2004.08.206Search in Google Scholar PubMed

Kapadia, C., Yousef, G.M., Mellati, A.A., Magklara, A., Wasney, G.A., and Diamandis, E.P. (2004b). Complex formation between human kallikrein 13 and serum protease inhibitors. Clin. Chim. Acta339, 157–167.10.1016/j.cccn.2003.10.009Search in Google Scholar PubMed

Kim, H., Scorilas, A., Katsaros, D., Yousef, G.M., Massobrio, M., Fracchioli, S., Piccinno, R., Gordini, G., and Diamandis, E.P. (2001). Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br. J. Cancer84, 643–650.10.1054/bjoc.2000.1649Search in Google Scholar PubMed PubMed Central

Kishi, T., Grass, L., Soosaipillai, A., Shimizu-Okabe, C., and Diamandis, E.P. (2003) Human kallikrein 8: immunoassay development and identification in tissue extracts and biological fluids. Clin. Chem.49, 87–96.10.1373/49.1.87Search in Google Scholar PubMed

Kishi, T., Soosaipillai, A., Grass, L., Little, S.P., Johnstone, E.M., and Diamandis, E.P. (2004). Development of an immunofluorometric assay and quantification of human kallikrein 7 in tissue extracts and biological fluids. Clin. Chem.50, 709–716.10.1373/clinchem.2003.029538Search in Google Scholar PubMed

Komatsu, N., Takata, M., Otsuki, N., Ohka, R., Amano, O., Takehara, K., and Saijoh, K. (2002). Elevated stratum corneum hydrolytic activity in Netherton syndrome suggests an inhibitory regulation of desquamation by SPINK5-derived peptides. J. Invest. Dermatol.118, 436–443.10.1046/j.0022-202x.2001.01663.xSearch in Google Scholar

Komatsu, N., Takata, M., Otsuki, N., Toyama, T., Ohka, R., Takehara, K., and Saijoh, K. (2003). Expression and localization of tissue kallikrein mRNAs in human epidermis and appendages. J. Invest. Dermatol.121, 542–549.10.1046/j.1523-1747.2003.12363.xSearch in Google Scholar

Komatsu, N., Saijoh, K., Toyama, T., Ohka, R., Otsuki, N., Hussack, G., Takehara, K., and Diamandis, E.P. (2005). Multiple tissue kallikrein mRNA and protein expression in normal skin and skin diseases. Br. J. Dermatol.153, 274–281.10.1111/j.1365-2133.2005.06754.xSearch in Google Scholar

Kraut, H., Frey, E.K., and Werle, E. (1930) Der Nachweis eines Kreislaufhormons in der Pankreasdrüse. Hoppe-Seyler's Z. Physiol. Chem.192, 1–21.Search in Google Scholar

Kreutzmann, P., Schulz, A., Standker, L., Forssmann, W.G., and Magert, H.J. (2004). Recombinant production, purification and biochemical characterization of domain 6 of LEKTI: a temporary Kazal-type-related serine proteinase inhibitor. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.803, 75–81.10.1016/j.jchromb.2003.07.016Search in Google Scholar

Kurlender, L., Borgono, C., Michael, I. P., Obiezu, C., Elliott, M.B., Yousef, G.M., and Diamandis, E.P. (2005). A survey of alternative transcripts of human tissue kallikrein genes. Biochim. Biophys. Acta1755, 1–14.10.1016/j.bbcan.2005.02.001Search in Google Scholar

Latham, J.P., Searle, P.F., Mautner, V., and James, N.D. (2000). Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res.60, 334–341.Search in Google Scholar

Li, B., Goyal, J., Dhar, S., Dimri, G., Evron, E., Sukumar, S., Wazer, D.E., and Band, V. (2001). CpG methylation as a basis for breast tumor-specific loss of NES1/kallikrein 10 expression. Cancer Res.61, 8014–8021.Search in Google Scholar

Lilja, H. (1985). A kallikrein-like serine protease in prostate fluid cleaves the predominant seminal vesicle protein. J. Clin. Invest.75, 1899–1903.10.1172/JCI112185Search in Google Scholar

Lin, H.K., Yeh, S., Kang, H.Y., and Chang, C. (2001). Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc. Natl. Acad. Sci. USA98, 7200–7205.10.1073/pnas.121173298Search in Google Scholar

Liu, X.L., Wazer, D.E., Watanabe, K., and Band, V. (1996). Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res.56, 3371–3379.Search in Google Scholar

Lovgren, J., Airas, K., and Lilja, H. (1999). Enzymatic action of human glandular kallikrein 2 (hK2). Substrate specificity and regulation by Zn²⁺ and extracellular protease inhibitors. Eur. J. Biochem.262, 781–789.Search in Google Scholar

Luo, L.Y., Grass, L., and Diamandis, E.P. (2000). The normal epithelial cell-specific 1 (NES1) gene is up-regulated by steroid hormones in the breast carcinoma cell line BT-474. Anticancer Res.20, 981–986.Search in Google Scholar

Luo, L.Y., Bunting, P., Scorilas, A., and Diamandis, E.P. (2001a). Human kallikrein 10: a novel tumor marker for ovarian carcinoma? Clin. Chim. Acta306, 111–118.10.1016/S0009-8981(01)00401-6Search in Google Scholar

Luo, L.Y., Grass, L., Howarth, D.J., Thibault, P., Ong, H., and Diamandis, E.P. (2001b). Immunofluorometric assay of human kallikrein 10 and its identification in biological fluids and tissues. Clin. Chem.47, 237–246.10.1093/clinchem/47.2.237Search in Google Scholar

Luo, L.Y., Grass, L., and Diamandis, E.P. (2003a). Steroid hormone regulation of the human kallikrein 10 (KLK10) gene in cancer cell lines and functional characterization of the KLK10 gene promoter. Clin. Chim. Acta337, 115–126.10.1016/j.cccn.2003.07.008Search in Google Scholar PubMed

Luo, L.Y., Katsaros, D., Scorilas, A., Fracchioli, S., Bellino, R., van Gramberen, M., de Bruijn, H., Henrik, A., Stenman, U.H., Massobrio, M., et al. (2003b). The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res.63, 807–811.Search in Google Scholar

Magklara, A., Grass, L., and Diamandis, E.P. (2000). Differential steroid hormone regulation of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) in breast cancer cell lines. Breast Cancer Res. Treat.59, 263–270.10.1023/A:1006304518750Search in Google Scholar

Magklara, A., Mellati, A.A., Wasney, G.A., Little, S.P., Sotiropoulou, G., Becker, G.W., and Diamandis, E.P. (2003). Characterization of the enzymatic activity of human kallikrein 6: autoactivation, substrate specificity, and regulation by inhibitors. Biochem. Biophys. Res. Commun.307, 948–955.10.1016/S0006-291X(03)01271-3Search in Google Scholar

Malm, J., Hellman, J., Hogg, P., and Lilja, H. (2000). Enzymatic action of prostate-specific antigen (PSA or hK3): substrate specificity and regulation by Zn²⁺, a tight-binding inhibitor. Prostate45, 132–139.10.1002/1097-0045(20001001)45:2<132::AID-PROS7>3.0.CO;2-3Search in Google Scholar

Markland, W., Roberts, B.L., and Ladner, R.C. (1996). Selection for protease inhibitors using bacteriophage display. Methods Enzymol.267, 28–51.10.1016/S0076-6879(96)67004-9Search in Google Scholar

Matsumura, M., Bhatt, A.S., Andress, D., Clegg, N., Takayama, T.K., Craik, C.S., and Nelson, P.S. (2005). Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries. Prostate62, 1–13.10.1002/pros.20101Search in Google Scholar

Michael, I.P., Sotiropoulou, G., Pampalakis, G., Magklara, A., Ghosh, M., Wasney, G., and Diamandis, E.P. (2005). Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J. Biol. Chem.280, 14628–14635.10.1074/jbc.M408132200Search in Google Scholar

Mikolajczyk, S.D., Millar, L.S., Marker, K.M., Grauer, L.S., Goel, A., Cass, M.M., Kumar, A., and Saedi, M.S. (1997). Ala217 is important for the catalytic function and autoactivation of prostate-specific human kallikrein 2. Eur. J. Biochem.246, 440–446.10.1111/j.1432-1033.1997.00440.xSearch in Google Scholar

Murtha, P., Tindall, D.J., and Young, C.Y. (1993). Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5' promoter region of the gene. Biochemistry32, 6459–6464.10.1021/bi00076a020Search in Google Scholar

Nakamura, T., Stephan, C., Scorilas, A., Yousef, G.M., Jung, K., and Diamandis, E.P. (2003). Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues. Urology61, 1042–1046.10.1016/S0090-4295(02)02443-3Search in Google Scholar

Ni, X., Zhang, W., Huang, K.C., Wang, Y., Ng, S.K., Mok, S.C., Berkowitz, R.S., and Ng, S.W. (2004). Characterisation of human kallikrein 6/protease M expression in ovarian cancer. Br. J. Cancer91, 725–731.10.1038/sj.bjc.6602041Search in Google Scholar

Noh, W.C., Mondesire, W.H., Peng, J., Jian, W., Zhang, H., Dong, J., Mills, G.B., Hung, M.C., and Meric-Bernstam, F. (2004). Determinants of rapamycin sensitivity in breast cancer cells. Clin. Cancer Res.10, 1013–1023.10.1158/1078-0432.CCR-03-0043Search in Google Scholar

Obiezu, C.V. and Diamandis, E.P. (2005). Human tissue kallikrein gene family: applications in cancer. Cancer Lett.224, 1–22.10.1016/j.canlet.2004.09.024Search in Google Scholar

Obiezu, C.V., Scorilas, A., Katsaros, D., Massobrio, M., Yousef, G.M., Fracchioli, S., Rigault de la Longrais, I.A., Arisio, R., and Diamandis, E.P. (2001). Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. Clin. Cancer Res.7, 2380–2386.Search in Google Scholar

Obiezu, C.V., Soosaipillai, A., Jung, K., Stephan, C., Scorilas, A., Howarth, D.H., and Diamandis, E.P. (2002). Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. Clin. Chem.48, 1232–1240.10.1093/clinchem/48.8.1232Search in Google Scholar

Obiezu, C.V., Shan, S.J., Soosaipillai, A., Luo, L.Y., Grass, L., Sotiropoulou, G., Petraki, C.D., Papanastasiou, P.A., Levesque, M.A., and Diamandis, E.P. (2005). Human kallikrein 4: quantitative study in tissues and evidence for its secretion into biological fluids. Clin. Chem.51, 1432–1442.10.1373/clinchem.2005.049692Search in Google Scholar

Oikonomopoulou, K., Hansen, K.K., Saifeddine, M., Vergnolle, N., Tea, I., Blaber, M., Blaber, S.I., Scarisbrick, I., Diamandis, E.P., and Hollenberg, M.D. (2006). Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs). Biol. Chem.387, 817–824.10.1515/BC.2006.104Search in Google Scholar

Pampalakis, G., Kurlender, L., Diamandis, E.P., and Sotiropoulou, G. (2004). Cloning and characterization of novel isoforms of the human kallikrein 6 gene. Biochem. Biophys. Res. Commun.320, 54–61.10.1016/j.bbrc.2004.04.205Search in Google Scholar

Peralba, J.M., DeGraffenried, L., Friedrichs, W., Fulcher, L., Grunwald, V., Weiss, G., and Hidalgo, M. (2003). Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin. Cancer Res.9, 2887–2892.Search in Google Scholar

Rehault, S., Brillard-Bourdet, M., Bourgeois, L., Frenette, G., Juliano, L., Gauthier, F., and Moreau, T. (2002). Design of new and sensitive fluorogenic substrates for human kallikrein hK3 (prostate-specific antigen) derived from semenogelin sequences. Biochim. Biophys. Acta1596, 55–62.10.1016/S0167-4838(02)00204-2Search in Google Scholar

Rehault, S., Monget, P., Mazerbourg, S., Tremblay, R., Gutman, N., Gauthier, F., and Moreau, T. (2001). Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Eur. J. Biochem.268, 2960–2968.10.1046/j.1432-1327.2001.02185.xSearch in Google Scholar PubMed

Riegman, P.H., Vlietstra, R.J., van der Korput, J.A., Brinkmann, A.O., and Trapman, J. (1991). The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol. Endocrinol.5, 1921–1930.10.1210/mend-5-12-1921Search in Google Scholar PubMed

Rittenhouse, H.G., Finlay, J.A., Mikolajczyk, S.D., and Partin, A.W. (1998). Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit. Rev. Clin. Lab. Sci.35, 275–368.10.1080/10408369891234219Search in Google Scholar PubMed

Rochette-Egly, C. (2003). Nuclear receptors: integration of multiple signalling pathways through phosphorylation. Cell. Signal.15, 355–366.10.1016/S0898-6568(02)00115-8Search in Google Scholar

Schuur, E.R., Henderson, G.A., Kmetec, L.A., Miller, J.D., Lamparski, H.G., and Henderson, D.R. (1996). Prostate-specific antigen expression is regulated by an upstream enhancer. J. Biol. Chem.271, 7043–7051.10.1074/jbc.271.12.7043Search in Google Scholar

Scorilas, A., Borgono, C.A., Harbeck, N., Dorn, J., Schmalfeldt, B., Schmitt, M., and Diamandis, E.P. (2004). Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. J. Clin. Oncol.22, 678–685.10.1200/JCO.2004.05.144Search in Google Scholar

Shigemasa, K., Gu, L., Tanimoto, H., O'Brien, T.J., and Ohama, K. (2004). Human kallikrein gene 11 (KLK11) mRNA overexpression is associated with poor prognosis in patients with epithelial ovarian cancer. Clin. Cancer Res.10, 2766–2770.10.1158/1078-0432.CCR-03-0269Search in Google Scholar

Shvartsman, H.S., Lu, K.H., Lee, J., Lillie, J., Deavers, M.T., Clifford, S., Wolf, J.K., Mills, G.B., Bast, R.C. Jr., Gershenson, D.M., and Schmandt, R. (2003). Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol. Oncol.90, 44–50.10.1016/S0090-8258(03)00257-9Search in Google Scholar

Sidiropoulis, M., Pampalakis, G., Sotiropoulou, G., Katsaros, D., and Diamandis E.P. (2005). Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers. Tumour Biol.26, 324–336.10.1159/000089290Search in Google Scholar PubMed

Stavropoulou, P., Gregorakis, A.K., Plebani, M., and Scorilas, A. (2005). Expression analysis and prognostic significance of human kallikrein 11 in prostate cancer. Clin. Chim. Acta357, 190–195.10.1016/j.cccn.2005.03.026Search in Google Scholar PubMed

Stephan, C., Yousef, G.M., Scorilas, A., Jung, K., Jung, M., Kristiansen, G., Hauptmann, S., Bharaj, B.S., Nakamura, T., Loening, S.A., and Diamandis, E.P. (2003). Quantitative analysis of kallikrein 15 gene expression in prostate tissue. J. Urol.169, 361–364.10.1097/00005392-200301000-00107Search in Google Scholar

Suzuki, S., Tadakuma, T., Kunitomi, M., Takayama, E., Sato, M., Asano, T., Nakamura, H., and Hayakawa, M. (2001). Liposome-mediated gene therapy using HSV-TK/ganciclovir under the control of human PSA promoter in prostate cancer cells. Urol. Int.67, 216–223.10.1159/000050991Search in Google Scholar PubMed

Takayama, T.K., McMullen, B.A., Nelson, P.S., Matsumura, M., and Fujikawa, K. (2001). Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry40, 15341–15348.10.1021/bi015775eSearch in Google Scholar PubMed

Tanimoto, H., Underwood, L.J., Shigemasa, K., Parmley, T.H., and O'Brien, T.J. (2001). Increased expression of protease M in ovarian tumors. Tumour Biol.22, 11–18.10.1159/000030150Search in Google Scholar PubMed

Wu, P., Leinonen, J., Koivunen, E., Lankinen, H., and Stenman, U.H. (2000). Identification of novel prostate-specific antigen-binding peptides modulating its enzyme activity. Eur. J. Biochem.267, 6212–6220.10.1046/j.1432-1327.2000.01696.xSearch in Google Scholar PubMed

Yoshimura, I., Suzuki, S., Tadakuma, T., and Hayakawa, M. (2001). Suicide gene therapy on LNCaP human prostate cancer cells. Int. J. Urol.8, S5–8.10.1046/j.1442-2042.2001.00327.xSearch in Google Scholar PubMed

Yousef, G.M. and Diamandis, E.P. (2001). The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr. Rev.22, 184–204.Search in Google Scholar

Yousef, G.M., Luo, L.Y., Scherer, S.W., Sotiropoulou, G., and Diamandis, E.P. (1999). Molecular characterization of zyme/protease M/neurosin (PRSS9), a hormonally regulated kallikrein-like serine protease. Genomics62, 251–259.10.1006/geno.1999.6012Search in Google Scholar PubMed

Yousef, G.M., Chang, A., Scorilas, A., and Diamandis, E.P. (2000). Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem. Biophys. Res. Commun.276, 125–133.10.1006/bbrc.2000.3448Search in Google Scholar PubMed

Yousef, G.M., Borgono, C.A., Scorilas, A., Ponzone, R., Biglia, N., Iskander, L., Polymeris, M.E., Roagna, R., Sismondi, P., and Diamandis, E.P. (2002a). Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis. Br. J. Cancer87, 1287–1293.10.1038/sj.bjc.6600623Search in Google Scholar PubMed PubMed Central

Yousef, G.M., Scorilas, A., Kyriakopoulou, L.G., Rendl, L., Diamandis, M., Ponzone, R., Biglia, N., Giai, M., Roagna, R., Sismondi, P., and Diamandis, E.P. (2002b). Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer. Clin. Chem.48, 1241–1250.10.1093/clinchem/48.8.1241Search in Google Scholar

Yousef, G.M., Polymeris, M.E., Grass, L., Soosaipillai, A., Chan, P.C., Scorilas, A., Borgono, C., Harbeck, N., Schmalfeldt, B., Dorn, J., et al. (2003a). Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Res.63, 3958–3965.Search in Google Scholar

Yousef, G.M., Polymeris, M.E., Yacoub, G.M., Scorilas, A., Soosaipillai, A., Popalis, C., Fracchioli, S., Katsaros, D., and Diamandis, E.P. (2003b). Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res.63, 2223–2227.Search in Google Scholar

Yousef, G.M., Borgono, C.A., Michael, I.P., and Diamandis, E.P. (2004). Cloning of a kallikrein pseudogene. Clin. Biochem.37, 961–967.10.1016/j.clinbiochem.2004.07.012Search in Google Scholar PubMed

Yu, D., Sakamoto, G.T., and Henderson, D.R. (1999). Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res.59, 1498–1504.Search in Google Scholar